Biohaven (BHVN) Q3 2025 earnings summary

Executive summary

• Focused on immunology, neuroscience, and oncology, with reprioritization to three key clinical programs: Kv7 ion channel modulation, MODE/TRAP protein degraders, and myostatin-activin pathway agents, including opakalim, BHV-1300, and BHV-1400.

• Advanced late-stage clinical programs in epilepsy, depression, autoimmune disease, obesity, and cancer, with several Phase 1–3 trials ongoing or planned.

• Initiated strategic cost optimization, prioritizing high-value programs and reducing annual direct R&D spend by approximately 60%.

• Restructured business priorities, pausing or halting non-priority programs to optimize resource allocation.

• No product revenue to date; operations funded by equity and debt, including a $250M note issuance in April 2025.

Financial highlights

• Net loss of $173.4M for Q3 2025 ($1.64 per share), compared to $160.3M in Q3 2024; net loss of $593.3M for the nine months ended September 30, 2025.

• R&D expenses were $141.2M in Q3 2025 (down $16.4M YoY), and $513.1M for the nine months (down $115.3M YoY, mainly due to a one-time $171.9M expense in 2024 for a milestone/royalty buyback).

• G&A expenses increased to $28.2M in Q3 2025 (up $7.7M YoY), and $89.5M for the nine months (up $22.7M YoY), driven by higher share-based compensation and legal costs.

• Cash, cash equivalents, marketable securities, and restricted cash totaled $263.8M as of September 30, 2025.

• Non-GAAP adjusted net loss for Q3 2025 was $155.9M ($1.47 per share), compared to $164.1M ($1.74 per share) in Q3 2024.

Outlook and guidance

• Cash, equivalents, marketable securities, and equity commitments expected to fund operations for at least one year from issuance.

• Additional capital will be required to execute business plans and pursue growth; future funding may come from equity, debt, or strategic transactions.

• Top-line results from Phase 2 study of opakalim in major depressive disorder expected in Q4 2025.

• Initial top-line results from two Phase 2/3 studies in focal epilepsy anticipated in 1H 2026.

• Phase 2 clinical trial for taldefgrobep alfa in obesity to begin in Q4 2025.